ReviewNeuroimaging Techniques to Assess Inflammation in Multiple Sclerosis
Introduction
Multiple Sclerosis (MS) is a chronic neurological disease that represents a leading cause of disability in young adults (Noseworthy et al., 2000). In the past twenty years magnetic resonance imaging (MRI) has played an increasing role in disease management and has become the most important tool for early diagnosis and for monitoring response to treatment. Moreover, advanced neuroimaging techniques contributed to the discovery of pathogenic mechanisms and the identification of new therapeutic targets, allowing the development of patient-customized treatment strategies.
Accordingly to the traditional view, MS is considered as a primarily inflammatory disorder of the brain and spinal cord, in which the focal lymphocytic infiltration leads to damage to myelin and axons. Inflammation is initially transient and followed by remyelination, therefore the early course of disease is mainly characterized by episodes of neurological dysfunction that usually recover, called relapses. Widespread microglial activation is associated with extensive and chronic neurodegeneration and leads to progressive accumulation of disability over time (Compston and Coles, 2008).
However, recent histopathologic and imaging studies have shown that significant damage to neuronal structures occurs since the earliest stages of the disease (Zipp and Aktas, 2006). Within this framework, Stys and collaborators (Stys et al., 2012) suggested that MS could be an immunological convolution between an underlying primary degenerative disorder and the host aberrant immune response, raising the hypothesis that the disease may origin from degeneration rather than from inflammation. Whatever the cause of MS, it is commonly accepted that inflammation and degeneration usually coexist in individual patients in varying degrees (Ciccarelli et al., 2014).
The introduction of disease modifying drugs changed the perspective of patients about disability accumulation, because therapy is able to reduce the amount of relapsing events in comparison to those expected from the natural course of the pathology (University of California et al., 2016). It is widely accepted that an early treatment of the disease ensures a better long-term prognosis (Comi et al., 2017), thus early identification of neuroinflammation is needed to accelerate the diagnostic process. Furthermore, the availability of treatments for MS is continuously growing, with several drugs developed in the past ten years mainly targeting inflammation at different levels (Comi et al., 2017). For these reasons, defining the presence or absence of inflammation on individual basis is a key point in choosing the therapy and monitoring the treatment response (Trojano et al., 2017). At this purpose, a panel of experts has recently suggested to add the presence of disease activity and progression as additional descriptors of the four subtypes identified in the original classification from 1996: relapsing-remitting (RR), in which neurological symptoms are followed by recovery; secondary progressive (SP), following the RR course and characterized by progressive clinical worsening in absence of acute symptoms; progressive relapsing (PR), characterized by the coexistence of both relapses and progression; primary progressive (PP), a less frequent form, characterized by gradual worsening since the beginning of the disease (Lublin and Reingold, 1996, Lublin et al., 2014). Accordingly to this revision, disease activity is defined as the presence of a clinical relapse and/or the presence of new lesions detected with MRI, i.e. gadolinium-enhancing lesions or either new or unequivocally enlarging lesions in T2-weighted (w) images (Lublin et al., 2014).
Relapses represent the clinical expression of inflammation, which includes the development of new, focal, and usually permanent lesions that are detectable by MRI. New lesions are heralded by breakdown of the blood–brain-barrier (BBB), are associated with perivenous inflammation, and are detected in the early phase of inflammation by MRI, as extrusion of gadolinium contrast agents across the altered BBB. However, the presence of a focal inflammatory lesion in the brain does not always lead to neurological signs or symptoms. MRI represents therefore the most sensitive tool to monitor inflammation in clinical practice: the occurrence of MRI lesions is now used to confirm diagnosis and has been validated as surrogate marker of relapse to monitor response to treatments (Sormani and Bruzzi, 2013).
Anyway the presence of a focal inflammatory lesion in the brain represents only an aspect of neuroinflammation. The identification of ectopic B cell follicles in the meninges suggests a sustained inflammation in progressive disease (Serafini et al., 2004, Howell et al., 2011). Indeed, one of the driving processes behind neurodegeneration and progression has been currently accepted to be a compartmentalized inflammation of the central nervous system (CNS) (Howell et al., 2011, Lassmann et al., 2012). Moreover, recent studies suggest the presence of diffuse inflammation related to microglial cells activation: at progressive stages, activated microglial cells have been demonstrated both at the edge of chronic focal lesions (called chronic active lesions), and throughout the normal-appearing WM (NAWM), i.e. the WM regions which have a normal appearance at the conventional MRI techniques (Airas et al., 2015, Frischer et al., 2015). New imaging techniques have been developed to study microglial activation as an important manifestation of the diffuse pathology which takes place outside the focal plaques in the NAWM (Herranz et al., 2016).
In this review, we will consider the role of neuroimaging in detecting inflammation in MS, focusing on the two specular aspects of technical development and applications. We principally address the role of MRI for both clinical and research purposes, but also refer to some studies based on positron emission tomography (PET) given their relevance in evaluating glial activation.
MS is characterized by the presence of focal lesions that involve both GM and WM, in the different stages of the disease, and that are well recognizable by applying various MRI sequences. It has been assessed that in MS tissue damage is not limited to focal plaques, but rather it swells beyond. To investigate the nature of the diffuse neuroinflammation and pathology, as well its severity and progression, innovative MR techniques have been developed (Ge et al., 2009). Nevertheless, the boundary between the detection of focal and diffuse damage is faded and some techniques are able both to observe diffuse inflammation and identify focal lesions, e. g. magnetic resonance spectroscopy, diffusion based imaging or positron emission tomography (respectively Chapter 5, 6 and 7). The main aim of this review will be to enlighten the different features of neuroinflammation and the MRI techniques that are able to detect them at best. We will focus on brain studies, leaving the assessment of inflammation in spinal cord to a further review.
Section snippets
Conventional MRI technique
Current diagnostic criteria for MS consider MRI as an essential tool to demonstrate dissemination in space (DIS) and time (DIT) of inflammatory lesions (Polman et al., 2011).
Conventional MRI sequences, performed by scanners with magnet strength of at least 1T, are able to detect WM focal lesions, thus allowing MS diagnosis and evaluation of treatment response. Conventional MRI techniques include sequences as fast spin-echo T2-w, dual spin-echo, T2-w fluid-attenuated inversion recovery (FLAIR)
Susceptibility weighted imaging (SWI)
Iron plays an important role in brain functions, i.e. oxygen transport, neurotransmitter synthesis and myelin production, and it generally creates deposits in normal aging. Anyway abnormal deposits of iron are revealed in neurological inflammation and diseases (Stankiewicz et al., 2007).
Histologically iron deposits surround MS lesions, especially in chronic active lesions, such as those lesions surrounded by an inflammatory rim of activated microglia and macrophages (Lassmann et al., 2012).
Double inversion recovery (DIR)
Widespread demyelination of the gray matter occurs in MS, as demonstrated by pathological studies, even in patients with a first clinical episode suggestive of MS (CIS, Peterson et al., 2001, Bø et al., 2003, Kutzelnigg et al., 2005). Recognition of cortical lesions can provide essential information in the diagnostic setting since they are very rare in neurological diseases other than MS.
In vivo visualization of cortical lesions has been demonstrated with ultra-high field MRI (7T) by Mainero
Magnetic resonance spectroscopy (MRS)
The content of metabolites is altered in brain regions damaged by inflammatory outcomes. Indeed, MS patients suffer from the alteration in the concentration of N-acetyl-aspartate, Choline, Inositol, Lactate (respectively NAA, Cho, Ins, Lac) and lipids. MRS is a non-invasive tool able to map the metabolites content through the magnetization properties of the metabolite protons and the relative Larmor frequencies, which are specific of the species (Buonocore and Maddock, 2015).
NAA is considered a
Diffusion based imaging
To observe microstructural damage that is not visible with conventional techniques, diffusion-weighted images have been found to be very effective. The diffusion paradigm is based on the properties of the water while flowing in compact tissues, thus how it is restricted by structures as axons and myelin in the WM, or neurons and glia in GM (Sbardella et al., 2013).
Diffusion sequences require the acquisition of several gradient directions, from three (Diffusion Weighted Images, DWI) to six and
Simultaneous positron emission tomography (PET) and magnetic resonance imaging (MRI)
In recent years PET and MRI has been extensively used to simultaneously or in different sessions enlighten several aspects of MS pathophysiology. Specifically, the combination of the two techniques allows the mapping of both structural damages and metabolic features.
PET is a minimally invasive nuclear medicine imaging technique that maps radiolabeled molecules (radioligands). Radioligands are injected intravenously and bind targets with high specificity, thus allowing an accurate detection and
Functional magnetic resonance imaging (fMRI)
fMRI is a procedure that allows to map neural activity by imaging the blood oxyhemoglobin changes related to the amount of energy used by brain cells: it is based on the blood-oxygen-level-dependent (BOLD) contrast. In task-related fMRI studies brain areas activated by a specific task (e.g. motor, visual, cognitive) can be mapped, thus allowing to relate definite brain areas to specific functions. fMRI studies may provide an indirect evidence of neuroinflammatory effects on brain tissue in MS.
New contrast agents
The role of inflammation in MS can be better inquired with new MRI techniques that involve the use of contrast agents able to cross the BBB, even if not brokendown (Ciccarelli et al., 2014).
Superparamagnetic ironoxide (SPIO) are endogenous particles that can be administered into the bloodstream in order to follow the immune-cells pathway by being phagocyted by the monocytes and shorten T1 and T2/T2∗ relaxation times, producing hypointense or hyperintense relatively weighted signals (Albrecht et
Conclusions
The growing development of MRI techniques has been beneficial for both clinical purpose and research activity. Clinically, these progresses have made possible an early diagnosis of MS with increased specificity, thus allowing a prompt treatment start. Moreover, several disease-modifying drugs are now available for patients with relapsing-remitting MS and the treatment has become more successful with long-lasting response. No evidence of disease activity needs to be assessed in all treated
Acknowledgment
We are grateful to Dr Caterina Mainero for her precious comments and suggestions.
This work was partially supported by the Italian Federation of Multiple Sclerosis (FISM), grant number 2013/5/1.
References (103)
- et al.
Assessment of lesion pathology in a new animal model of MS by multiparametric MRI and DTI
Neuroimage
(2012) - et al.
Translocator protein 18 kDa (TSPO): Molecular sensor of brain injury and repair
Pharmacol Ther
(2008) - et al.
Pathogenesis of multiple sclerosis: insights from molecular and metabolic imaging
Lancet Neurol
(2014) - et al.
Evolving concepts in the treatment of relapsing multiple sclerosis
The Lancet
(2017) - et al.
Multiple sclerosis
The Lancet
(2008) - et al.
A new imaging modality to non-invasively assess multiple sclerosis pathology
J Neuroimmunol
(2017) - et al.
Magnetic resonance spectroscopy as a measure of brain damage in multiple sclerosis
J Neurol Sci
(2005) - et al.
MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines
Lancet Neurol
(2016) - et al.
Microglia activation in multiple sclerosis black holes predicts outcome in progressive patients: An in vivo [(11)C](R)-PK11195-PET pilot study
Neurobiol Dis
(2014) - et al.
TSPO in a murine model of Sandhoff disease: presymptomatic marker of neurodegeneration and disease pathophysiology
Neurobiol Dis
(2016)
1H MR spectroscopy of inflammation, infection and ischemia of the brain
Eur J Radiol
Cortical adaptation in patients with MS: a cross-sectional functional MRI study of disease phenotypes
Lancet Neurol
Immune Surveillance of the CNS following Infection and Injury
Trends Immunol
MRI lesions as a surrogate for relapses in multiple sclerosis: a meta-analysis of randomised trials
Lancet Neurol
Iron in chronic brain disorders: Imaging and neurotherapeutic implications
Neurotherapeutics
Diffusion spectrum magnetic resonance imaging (DSI) tractography of crossing fibers
NeuroImage
Seven-tesla phase imaging of acute multiple sclerosis lesions: A new window into the inflammatory process
Ann Neurol
Gadolinium-based MRI characterization of leptomeningeal inflammation in multiple sclerosis
Neurology
In vivo PET imaging demonstrates diminished microglial activation after fingolimod treatment in an animal model of multiple sclerosis
J Nucl Med
In vivo imaging of human neuroinflammation
ACS Chem Neurosci
Tracking iron in multiple sclerosis: a combined imaging and histopathological study at 7 Tesla
Brain
The peripheral benzodiazepine binding site in the brain in multiple sclerosis Quantitative in vivo imaging of microglia as a measure of disease activity
Brain
Subpial demyelination in the cerebral cortex of multiple sclerosis patients
J Neuropathol Exp Neurol
Magnetic resonance spectroscopy of the brain: a review of physical principles and technical methods
Rev Neurosci
1H-MRS quantification of tNA and tCr in patients with multiple sclerosis: a meta-analytic review
Brain
In vivo assessment of brain white matter inflammation in multiple sclerosis with 18F-PBR111 PET
J Nucl Med
Translocator positron-emission tomography and magnetic resonance spectroscopic imaging of brain glial cell activation in multiple sclerosis
Mult Scler
PET visualization of microglia in multiple sclerosis patients using [11C]PK11195
Eur J Neurol
Changes in brain functional connectivity patterns are driven by an individual lesion in MS: a resting-state fMRI study
Brain Imaging Behav
Development of chemical exchange saturation transfer at 7T
Magn Reson Med
Nonconventional MRI and microstructural cerebral changes in multiple sclerosis
Nat Rev Neurol
Reliability of cortical lesion detection on double inversion recovery MRI applying the MAGNIMS-Criteria in multiple sclerosis patients within a 16-months period
PLoS One
Guidelines from The Italian Neurological and Neuroradiological Societies for the use of magnetic resonance imaging in daily life clinical practice of multiple sclerosis patients
Neurol Sci
Metabolic patterns in chronic multiple sclerosis lesions and normal-appearing white matter: intraindividual comparison by using 2D MR spectroscopic imaging
Radiology
Prediction of disease activity in models of multiple sclerosis by molecular magnetic resonance imaging of P-selectin
Proc Natl Acad Sci U S A
Clinical and pathological insights into the dynamic nature of the white matter multiple sclerosis plaque
Ann Neurol
Diminished visibility of cerebral venous vasculature in multiple sclerosis by susceptibility-weighted imaging at 3.0 Tesla
J Magn Reson Imaging
Increased PK11195-PET binding in normal-appearing white matter in clinically isolated syndrome
Brain
“No evident disease activity”: The use of combined assessments in the management of patients with multiple sclerosis
Mult Scler
“Gadolinium-Phobia:” not a helpful “criterion” for indication for gadolinium-based contrast agent administration in multiple sclerosis
Radiology
Multiple sclerosis lesion formation and early evolution revisited: A weekly high-resolution magnetic resonance imaging study
Mult Scler
Characterizing iron deposition in multiple sclerosis lesions using susceptibility weighted imaging
J Magn Reson Imaging
Quantitative in vivo magnetic resonance imaging of multiple sclerosis at 7 Tesla with sensitivity to iron
Ann Neurol
Neuroinflammatory component of gray matter pathology in multiple sclerosis
Ann Neurol
Translocator protein and new targets for neuroinflammation
Clin Transl Imaging
Meningeal inflammation is widespread and linked to cortical pathology in multiple sclerosis
Brain
Characterization of axonal disease in patients with multiple sclerosis using high-gradient-diffusion MR imaging
Radiology
Default mode network disruption secondary to a lesion in the anterior thalamus
Arch Neurol
High signal intensity in the dentate nucleus and globus pallidus on unenhanced T1-weighted MR images: relationship with increasing cumulative dose of a gadolinium-based contrast material
Radiology
Cited by (38)
Good bacteria, oxidative stress and neurological disorders: Possible therapeutical considerations
2022, Life SciencesCitation Excerpt :It is determined that a combination of genetic and environmental factors are involved in the pathogenesis of MS. The most extensively recognized hypothesis is that auto-reactive T and B cells cause myelin and axonal damage, and neurodegeneration [319,320]. The main neuropathological hallmark of MS pathology is formation of demyelinating plaques in the white and grey matter of the CNS [321]. The situation of these plaques within the CNS is variable over time and is introduced as a critical determinant of the clinical consequence.
Altered sensorimotor integration in multiple sclerosis: A combined neurophysiological and functional MRI study
2021, Clinical NeurophysiologyCitation Excerpt :Cortical overload may interfere with motor performance by reducing network flexibility and altering the temporal activation of neural structures in the network that controls movement execution. Overall, the present findings are consistent with previous suggestions that boosting the synchronization between cerebral areas may not necessarily be beneficial in MS (Meijer et al., 2018; Tommasin et al., 2019; Tona et al., 2014), but indeed may represent either a failed attempt at circuit rearrangement in order to overcome structural damage or a detrimental effect of rsFC disruption due to the disease itself. Altered mechanisms of sensorimotor integration have been also reported in patients with Parkinson’s disease (Conte et al., 2017a).
N-acetyl cysteine administration affects cerebral blood flow as measured by arterial spin labeling MRI in patients with multiple sclerosis
2021, HeliyonCitation Excerpt :Further, a MRS study using high doses of oral NAC (600 mg) did not find significant increases in glutathione in the brain [56]. Conversely, intravenous NAC administration increased brain glutathione levels [57]. Therefore, we decided to use a combination of both oral and intravenous administration in an effort to accommodate the logistical difficulties in receiving an injection multiple times a week while also addressing the low bioavailability of oral NAC.
Non-invasive MRI windows to neuroinflammation
2019, NeuroscienceThe clinical value of deep gray matter 3T MRI perfusion in patients with multiple sclerosis
2023, Romanian Journal of Neurology/ Revista Romana de Neurologie